Phospho-IGF1R (Tyr1346) Antibody

What is the specificity of Phospho-IGF1R (Tyr1346) antibody?

Phospho-IGF1R (Tyr1346) antibody specifically detects endogenous levels of IGF1 Receptor only when phosphorylated at tyrosine 1346. This antibody recognizes the phosphorylated form of the receptor through specific binding to a synthesized phosphopeptide derived from human IGF1R around the phosphorylation site of tyrosine 1346, commonly with the sequence motif QPyAH . The high specificity is achieved through sequential chromatography purification on both phospho- and non-phospho-peptide affinity columns, which significantly reduces cross-reactivity with unphosphorylated IGF1R or other phosphorylated proteins .

Which species does the Phospho-IGF1R (Tyr1346) antibody react with?

The antibody demonstrates consistent reactivity with human, mouse, and rat species . This cross-species reactivity is due to the high conservation of the tyrosine 1346 phosphorylation site across mammalian species. Some manufacturers have conducted predictive reactivity analyses suggesting potential cross-reactivity with additional species including pig, bovine, rabbit, dog, chicken, and Xenopus , though these applications would require validation by researchers before use in experimental settings.

What are the recommended applications for Phospho-IGF1R (Tyr1346) antibody?

The antibody is validated for multiple research applications:

Optimal dilutions may vary between antibody manufacturers and specific experimental conditions, requiring optimization for each laboratory setting .

How should Phospho-IGF1R (Tyr1346) antibody be stored?

For optimal stability and activity retention, store the antibody at -20°C for up to one year from the date of receipt . The antibody is typically supplied in a liquid formulation containing PBS with 50% glycerol, 0.5% BSA, and 0.02% sodium azide as preservatives . This formulation prevents freeze-thaw damage and maintains antibody integrity. Repeated freeze-thaw cycles should be avoided as they can lead to protein denaturation and loss of binding activity . For working solutions, aliquoting is strongly recommended to minimize freeze-thaw cycles.

What is the biological significance of Tyr1346 phosphorylation compared to other IGF1R phosphorylation sites?

While the triple phosphorylation of tyrosines 1161, 1165, and 1166 in the kinase activation loop is well-characterized for optimal IGF1R activity , the phosphorylation at Tyr1346 represents a distinct regulatory mechanism. Tyr1346 phosphorylation occurs in the C-terminal domain and is implicated in the recruitment of specific downstream signaling molecules and scaffold proteins. Unlike the activation loop phosphorylation that directly affects kinase activity, Tyr1346 phosphorylation appears to modulate signaling pathway selectivity .

Research data suggest that differential phosphorylation patterns, including at Tyr1346, may contribute to the diversity of cellular responses to IGF1 stimulation. For example, some studies indicate that Tyr1346 phosphorylation may preferentially activate the PI3K/Akt pathway over the MAPK pathway, potentially explaining the observed differences in anti-apoptotic versus proliferative responses to IGF1 in various cell types .

How does serine phosphorylation of IGF1R interact with tyrosine phosphorylation at Tyr1346?

Research has demonstrated complex interplay between serine and tyrosine phosphorylation events on IGF1R. Specifically, mutation of Ser-1248 (S1248A) enhances IGF1R in vitro kinase activity, autophosphorylation, and downstream Akt/mTOR signaling . This suggests that serine phosphorylation may act as a negative regulator of receptor tyrosine kinase activity.

The relationship between Ser-1248 phosphorylation and Tyr1346 phosphorylation appears to be hierarchical. Evidence indicates that increased serine phosphorylation at Ser-1248 by GSK-3β reduces tyrosine phosphorylation at multiple sites, including Tyr1346. Conversely, inhibition of serine phosphorylation can enhance detection of phospho-Tyr1346, potentially affecting experimental outcomes when using phospho-specific antibodies . This cross-regulation highlights the importance of considering multiple phosphorylation events when interpreting IGF1R signaling experiments.

What methodological approaches can distinguish between IGF1R and insulin receptor phosphorylation when using phospho-specific antibodies?

Distinguishing between IGF1R and insulin receptor (INSR) phosphorylation presents a significant technical challenge due to their high sequence homology (84% in the tyrosine kinase domain) and formation of hybrid receptors in many tissues . Several methodological approaches can address this challenge:

• Immunoprecipitation followed by Western blotting: Initial immunoprecipitation with receptor-specific antibodies targeting non-homologous regions, followed by detection with phospho-specific antibodies .

• Two-step ELISA approaches: Using capture antibodies specific to either IGF1R or INSR extracellular domains, followed by detection with phospho-specific antibodies .

• Control experiments with receptor-selective ligands: Using IGF1 (high affinity for IGF1R), IGF2 (binds both receptors), and insulin (high affinity for INSR) to determine the specificity of the phosphorylation response .

• siRNA knockdown validation: Selective knockdown of IGF1R or INSR to verify antibody specificity in cellular contexts where both receptors are expressed .

These techniques, often used in combination, provide more definitive determination of receptor-specific phosphorylation events.

What are the critical considerations for sample preparation when detecting phospho-IGF1R (Tyr1346)?

Successful detection of phospho-IGF1R (Tyr1346) requires careful attention to sample preparation to preserve phosphorylation status:

• Rapid sample processing: Immediate processing after tissue collection or cell harvesting is essential to prevent phosphatase activity .

• Phosphatase inhibitors: Include multiple phosphatase inhibitors in lysis buffers (e.g., sodium orthovanadate (1 mM), sodium fluoride (10 mM), β-glycerophosphate (10 mM)) .

• Lysis buffer composition: Use non-denaturing buffers containing 1% NP-40 or Triton X-100, 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), with protease inhibitors (PMSF, aprotinin, leupeptin) .

• Temperature control: Maintain samples at 4°C throughout processing to minimize phosphatase activity .

• Stimulation conditions: For positive controls, stimulate cells with IGF-1 (50-100 ng/ml) for 5-10 minutes before lysis to maximize phosphorylation at Tyr1346 .

Following these protocols significantly improves detection sensitivity and reduces false-negative results when assessing phosphorylation status.

How can immunohistochemical detection of phospho-IGF1R (Tyr1346) be optimized in formalin-fixed, paraffin-embedded tissues?

Detecting phospho-epitopes in fixed tissues presents unique challenges that can be addressed through these methodological approaches:

• Antigen retrieval optimization: Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) should be compared to determine optimal conditions for phospho-Tyr1346 detection .

• Signal amplification systems: Consider using polymer-based detection systems or tyramide signal amplification to enhance sensitivity when detecting low-abundance phospho-epitopes .

• Phosphatase controls: Always include serial sections treated with lambda phosphatase as negative controls to confirm phospho-specificity of staining .

• Blocking optimization: Extended blocking (2-3 hours) with 5-10% normal serum from the same species as the secondary antibody, supplemented with 1% BSA, reduces background staining .

• Validation with non-phospho antibodies: Parallel staining with antibodies recognizing total IGF1R provides context for interpreting phospho-specific signals .

The immunohistochemical protocol validated for phospho-IGF1R (Tyr1346) antibody demonstrates specific staining in human brain sections, with signal abolishment when the antibody is pre-incubated with the immunizing phosphopeptide .

What strategies can minimize non-specific binding when using phospho-IGF1R (Tyr1346) antibody in Western blot analysis?

Several methodological approaches can enhance specificity in Western blot applications:

• Membrane blocking optimization: Using 5% BSA in TBST rather than milk is essential, as milk contains phosphoproteins that can interact with phospho-specific antibodies, generating background .

• Antibody dilution and incubation conditions: Optimal dilutions range from 1:500-1:2000, with overnight incubation at 4°C providing better signal-to-noise ratios than shorter incubations at room temperature .

• Washing buffers: Using TBST with higher Tween-20 concentrations (0.1-0.3%) for more stringent washing conditions can reduce non-specific binding .

• Peptide competition controls: Including parallel experiments where the antibody is pre-incubated with the phosphopeptide immunogen provides definitive evidence of binding specificity .

• Appropriate molecular weight markers: The expected molecular weight of full-length phosphorylated IGF1R is approximately 155 kDa, while the beta subunit containing the phosphorylated Tyr1346 runs at approximately 95 kDa .

Implementation of these optimization strategies significantly improves the reliability of phospho-IGF1R (Tyr1346) detection in complex biological samples.

How can researchers differentiate between specific and non-specific signals when using phospho-IGF1R (Tyr1346) antibody?

Distinguishing specific from non-specific signals requires careful experimental controls and analysis:

• Positive control selection: Lysates from IGF1-stimulated cells known to express IGF1R (e.g., MCF-7, HEK293, NIH/3T3) serve as reliable positive controls .

• Negative control implementation: Use samples treated with IGF1R tyrosine kinase inhibitors (e.g., BMS-754807, NVP-AEW541) or lambda phosphatase-treated samples to confirm signal specificity .

• Competition assays: Pre-incubation of the antibody with increasing concentrations of the phosphopeptide immunogen should progressively reduce specific signals .

• Molecular weight verification: Specific signals should correspond to the expected molecular weight of IGF1R (~155 kDa for full-length receptor or ~95 kDa for the beta subunit) .

• Signal correlation with stimulus: Signal intensity should increase with IGF1 stimulation duration/concentration and decrease with inhibitor treatment in a dose-dependent manner .

These validation steps collectively provide confidence in data interpretation and help differentiate true phospho-IGF1R (Tyr1346) signals from potential artifacts.

What factors affect the detection sensitivity of phospho-IGF1R (Tyr1346) antibody in various applications?

Multiple factors influence detection sensitivity across different experimental platforms:

Understanding these factors allows researchers to troubleshoot experimental issues and optimize protocols for maximum detection sensitivity.

How can researchers verify that phospho-IGF1R (Tyr1346) antibody is detecting the intended phosphorylation site in their experimental system?

Definitive verification of phosphorylation site specificity requires multiple approaches:

• Site-directed mutagenesis: Generate Tyr1346 to Phe (Y1346F) mutant IGF1R expression constructs. When expressed, these mutants should not be recognized by the phospho-specific antibody despite IGF1 stimulation .

• Mass spectrometry validation: Immunoprecipitate IGF1R from samples and perform mass spectrometry analysis to confirm phosphorylation at Tyr1346 correlates with antibody detection .

• Phospho-peptide array analysis: Test antibody against arrays containing various IGF1R phospho-peptides to confirm specific recognition of the Tyr1346 phospho-site versus other phosphorylated IGF1R residues .

• Correlation with other phosphorylation sites: Compare phosphorylation kinetics at Tyr1346 with other well-characterized IGF1R phosphorylation sites (e.g., Tyr1131, Tyr1135, Tyr1136) following receptor stimulation .

• Phosphatase treatment: Treating samples with lambda phosphatase should eliminate antibody recognition if the binding is truly phosphorylation-dependent .

These verification strategies provide comprehensive evidence for phospho-site specificity, ensuring reliable interpretation of experimental data.

How can phospho-IGF1R (Tyr1346) antibody be used to evaluate IGF1R inhibitors in cancer research?

Phospho-IGF1R (Tyr1346) antibody provides valuable tools for assessing IGF1R inhibitor efficacy:

• Dose-response analysis: Quantify changes in Tyr1346 phosphorylation across inhibitor concentration ranges using Western blot or ELISA to determine IC50 values .

• Time-course evaluation: Monitor the duration of IGF1R inhibition following single-dose treatment by assessing Tyr1346 phosphorylation status at various time points .

• Pathway selectivity assessment: Compare inhibition of Tyr1346 phosphorylation with effects on downstream pathways (PI3K/Akt versus MAPK) to characterize inhibitor selectivity profiles .

• In vivo efficacy verification: Use immunohistochemistry with phospho-IGF1R (Tyr1346) antibody on tumor biopsies from treated animals to confirm target engagement and pathway inhibition .

• Resistance mechanism investigation: Monitor changes in Tyr1346 phosphorylation in models of acquired resistance to identify pathway reactivation or compensatory signaling mechanisms .

These applications provide crucial insights for preclinical development and mechanistic understanding of IGF1R-targeted therapeutics.

What approaches enable multiplexed analysis of IGF1R phosphorylation at Tyr1346 with other signaling pathways?

Modern research often requires simultaneous analysis of multiple phosphorylation events:

• Multiplex Western blotting: Sequential probing of blots with phospho-specific antibodies (stripping between each) allows comparison of Tyr1346 phosphorylation with other signaling pathways (Akt, ERK, etc.) .

• Phospho-flow cytometry: Combine phospho-IGF1R (Tyr1346) antibody with antibodies against other phospho-proteins for single-cell analysis of pathway activation using fluorescently labeled secondary antibodies .

• Proximity ligation assays: Detect interactions between phospho-IGF1R (Tyr1346) and potential binding partners in situ with subcellular resolution by combining phospho-specific antibodies with protein-specific antibodies .

• Multi-parameter IHC/IF: Apply multispectral imaging techniques to simultaneously visualize phospho-IGF1R (Tyr1346) alongside other markers in tissue sections, enabling spatial context analysis .

• Phospho-protein arrays: Use reverse-phase protein arrays with phospho-IGF1R (Tyr1346) antibody alongside other pathway-specific antibodies for high-throughput screening of phosphorylation networks .

These multiplexed approaches provide comprehensive signaling network analysis beyond single-pathway assessment.

How can phospho-IGF1R (Tyr1346) antibody be applied in studying crosstalk between IGF1R and other receptor tyrosine kinases?

Investigating receptor crosstalk requires specialized methodological approaches:

• Co-immunoprecipitation studies: Immunoprecipitate with phospho-IGF1R (Tyr1346) antibody followed by immunoblotting for other receptors (EGFR, HER2, INSR) to detect physical interactions after ligand stimulation .

• Sequential stimulation experiments: Analyze how pre-stimulation with EGF, insulin, or other growth factors affects IGF1-induced Tyr1346 phosphorylation to identify positive or negative crosstalk mechanisms .

• Inhibitor combination studies: Combine IGF1R inhibitors with inhibitors of other RTKs to assess phosphorylation at Tyr1346 and determine synergistic or antagonistic pathway interactions .

• Receptor co-localization analysis: Use phospho-IGF1R (Tyr1346) antibody in combination with antibodies against other RTKs for confocal microscopy to visualize potential co-localization after stimulation .

• Transcriptional feedback analysis: Correlate changes in Tyr1346 phosphorylation with alterations in the expression of genes regulating other RTKs to identify feedback mechanisms .

These approaches reveal complex signaling networks that may be critical for understanding therapeutic resistance mechanisms and developing effective combination strategies.